Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.

Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T.

Mol Cancer Ther. 2006 Nov;5(11):2634-43.

2.

The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model.

Ohno H, Uemura Y, Murooka H, Takanashi H, Tokieda T, Ohzeki Y, Kubo K, Serizawa I.

Eur J Immunol. 2008 Jan;38(1):283-91.

3.

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

Watanabe K, Hirata M, Tominari T, Matsumoto C, Fujita H, Yonekura K, Murphy G, Nagase H, Miyaura C, Inada M.

J Biol Chem. 2016 Sep 30;291(40):20891-20899. Epub 2016 Aug 18.

4.

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.

Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ.

Mol Cancer Ther. 2009 Nov;8(11):3151-61. doi: 10.1158/1535-7163.MCT-09-0255. Epub 2009 Nov 3.

5.

The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis.

Uemura Y, Ohno H, Ohzeki Y, Takanashi H, Murooka H, Kubo K, Serizawa I.

J Neuroimmunol. 2008 Mar;195(1-2):73-80. doi: 10.1016/j.jneuroim.2008.01.015. Epub 2008 Apr 2.

PMID:
18378004
6.

High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.

Fujita H, Gomori A, Fujioka Y, Kataoka Y, Tanaka K, Hashimoto A, Suzuki T, Ito K, Haruma T, Yamamoto-Yokoi H, Harada N, Sakuragi M, Oda N, Matsuo K, Inada M, Yonekura K.

PLoS One. 2016 Oct 13;11(10):e0164830. doi: 10.1371/journal.pone.0164830. eCollection 2016.

7.

Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.

Kimura K, Kitaura H, Fujii T, Hakami ZW, Takano-Yamamoto T.

FEMS Immunol Med Microbiol. 2012 Mar;64(2):219-27. doi: 10.1111/j.1574-695X.2011.00888.x. Epub 2011 Dec 5.

8.
9.

The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.

Kim HJ, Yoon HJ, Choi JY, Lee IK, Kim SY.

J Leukoc Biol. 2014 Feb;95(2):337-45. doi: 10.1189/jlb.0713356. Epub 2013 Oct 15.

11.

M-CSF mediates TNF-induced inflammatory osteolysis.

Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL.

J Clin Invest. 2005 Dec;115(12):3418-27. Epub 2005 Nov 17.

12.

Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.

Logan JG, Sophocleous A, Marino S, Muir M, Brunton VG, Idris AI.

J Bone Miner Res. 2013 May;28(5):1229-42. doi: 10.1002/jbmr.1847.

13.

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.

Furugaki K, Moriya Y, Iwai T, Yorozu K, Yanagisawa M, Kondoh K, Fujimoto-Ohuchi K, Mori K.

Clin Exp Metastasis. 2011 Oct;28(7):649-59. doi: 10.1007/s10585-011-9398-4. Epub 2011 Jun 18.

14.

Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.

El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M, Kamel S.

Eur J Pharmacol. 2006 Dec 3;551(1-3):27-33. Epub 2006 Sep 16.

PMID:
17049513
15.

Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.

Sasaki A, Alcalde RE, Nishiyama A, Lim DD, Mese H, Akedo H, Matsumura T.

Cancer Res. 1998 Feb 1;58(3):462-7.

17.

c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.

Paniagua RT, Chang A, Mariano MM, Stein EA, Wang Q, Lindstrom TM, Sharpe O, Roscow C, Ho PP, Lee DM, Robinson WH.

Arthritis Res Ther. 2010;12(1):R32. doi: 10.1186/ar2940. Epub 2010 Feb 24.

18.

Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation.

Vanhara P, Lincová E, Kozubík A, Jurdic P, Soucek K, Smarda J.

Differentiation. 2009 Nov;78(4):213-22. doi: 10.1016/j.diff.2009.07.008. Epub 2009 Aug 19.

PMID:
19695766
19.

Inhibition of osteoclastogenesis by RNA interference targeting RANK.

Ma R, Xu J, Dong B, Kauther MD, Jäger M, Wedemeyer C.

BMC Musculoskelet Disord. 2012 Aug 22;13:154. doi: 10.1186/1471-2474-13-154.

20.

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T.

J Exp Med. 2000 Jan 17;191(2):275-86.

Supplemental Content

Support Center